ALEC ALECTOR

Alector to Participate at Virtual Investor Conferences in September

Alector to Participate at Virtual Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in fireside chats at the following upcoming virtual investor conferences:

  • Citi’s 15th Annual BioPharma Virtual Conference, Thursday, September 10, 2020, at 11:40 a.m. ET
  • Morgan Stanley 18th Annual Global Healthcare Conference, Monday, September 14, 2020, at 12:00 p.m. ET

Live webcasts of each fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at . Replays of the webcasts will be available on the Alector website for 30 days following the event.

About Alector

Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector is developing a broad portfolio of programs designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. The Company’s product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. Alector is headquartered in South San Francisco, California. For additional information, please visit 

Contacts

Media:

Erica Jefferson

Vice President, Communications and Public Affairs

Alector, Inc.

301-928-4650

1AB

Dan Budwick

973-271-6085

or

Investors:

Alector, Inc.

EN
03/09/2020

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Bus...

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO. “Neil has...

December 12, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Bank of America CNS Therapeutics Confere...

Alector to Participate in the Bank of America CNS Therapeutics Conference SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Bank of America CNS Therapeutics Conference, being held virtually on Monday, December 8, 2025, at 2:25 pm ET. A webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors ...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Third Quarter 2025 Financial Results and Provides Busi...

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update Selected lead candidates AL137 for the company’s Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson’s disease; both advancing toward IND-enabling studies Advancing ABC-enabled Tau, Alpha Synuclein and NLRP3 siRNA programs targeting peripheral delivery of novel therapies for neurodegenerative disorders Independent interim analysis for the PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101) in ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Announces Topline Results from Latozinemab Phase 3 Trial in In...

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). In the 96-week, dou...

October 21, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Virtual Research and Development Event Highlighting PG...

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs --Agenda to feature latozinemab and AL101, along with progress in Alector Brain Carrier–enabled programs, including new lead candidates-- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced management will host a virtual event to discuss the company’s progranulin (PGRN) franchise and ...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch